Exchange: NASDAQ·Updated 07:30 PM EDT
FDMT logo

FDMT 4D Molecular Therapeutics Inc

$14.68
$0.27
(1.84%)
Today
Closed $14.97
$0.29
(1.94%)
After Hours
Reported EarningsAug 13
Mkt Cap$812.09M
Vol420,636.00

About FDMT

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. The company combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine creates a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
47

Neutral Sentiment

How do you feel about FDMT?

Advertisement|Remove ads.